1. Market Research
  2. > Pharmaceutical
  3. > Drug and Medication Market Trends
  4. > Drug and Medication Analysis & Statistics in the United Kingdom, October 2013 (p3)

Drug and Medication Analysis & Statistics in the United Kingdom, October 2013 (p3)

61-90 of about 100 reports

Purchase Reports From Reputable Market Research Publishers

2014 Analysis of the UK Clinical Chemistry and Immunodiagnostic Market: Sales Forecasts, Supplier Shares, Competitive Strategies

2014 Analysis of the UK Clinical Chemistry and Immunodiagnostic Market: Sales Forecasts, Supplier Shares, Competitive Strategies

  • $ 3 950
  • Industry report
  • October 2013
  • by Venture Planning Group

2014 Analysis of the UK Clinical Chemistry and Immunodiagnostic Market: Sales Forecasts, Supplier Shares, Competitive Strategies is a new strategic analysis of major business opportunities emerging in ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
NeisVac-C (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

NeisVac-C (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • September 2013
  • by Global Data

NeisVac-C (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Summary Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset ...

  • Industries : Drug and Medication
  • Countries : United Kingdom, World
Physician Views: How do European cardiologists perceive oral anticoagulants versus warfarin? – Is Eliquis, Pradaxa or Xarelto their favoured option?

Physician Views: How do European cardiologists perceive oral anticoagulants versus warfarin? – Is Eliquis, Pradaxa or Xarelto their favoured option?

  • $ 645
  • Industry report
  • September 2013
  • by Firstword Pharma

Sales forecasts for Bristol-Myers Squibb and Pfizer's anticoagulant product Eliquis have declined notably in recent months. According to Bloomberg, current consensus estimates suggest 2018 global revenues ...

  • Industries : Drug and Medication
  • Countries : Europe, United Kingdom, United States
Physician Views – How do European cardiologists perceive oral anticoagulants versus warfarin? – Is Eliquis, Pradaxa or Xarelto their favoured option?

Physician Views – How do European cardiologists perceive oral anticoagulants versus warfarin? – Is Eliquis, Pradaxa or Xarelto their favoured option?

  • $ 645
  • Industry report
  • September 2013
  • by Firstword Pharma

Scope Sales forecasts for Bristol-Myers Squibb and Pfizer's anticoagulant product Eliquis have declined notably in recent months. According to Bloomberg, current consensus estimates suggest 2018 global ...

  • Industries : Drug and Medication
  • Countries : Europe, United Kingdom, United States
UK Injectables Market Outlook to 2017

UK Injectables Market Outlook to 2017

  • $ 1 200
  • Industry report
  • September 2013
  • by RNCOS

Injectables occupy a considerable prominence in UK irrespective of diminishing growth in the pharmaceutical market for 2-3 years. The advancements in technology up-gradation and investments have provided ...

  • Industries : Pharmaceutical, Drug and Medication, Pathology
  • Countries : United Kingdom
PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • July 2013
  • by Global Data

PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis ...

  • Industries : Drug and Medication, Pathology
  • Countries : United Kingdom
Albiglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Albiglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Company report
  • July 2013
  • by Global Data

Albiglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Albiglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type ...

  • Industries : Drug and Medication, Pathology
  • Countries : United Kingdom
PharmaPoint: Postmenopausal Vaginal Atrophy - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - UK Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • July 2013
  • by Global Data

PharmaPoint: Postmenopausal Vaginal Atrophy - UK Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade, ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Company report
  • July 2013
  • by Global Data

Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type ...

  • Industries : Pathology, Drug and Medication
  • Countries : United Kingdom
Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Company report
  • July 2013
  • by Global Data

Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type ...

  • Industries : Pathology, Drug and Medication
  • Countries : United Kingdom
Ear Care in the United Kingdom

Ear Care in the United Kingdom

  • $ 1 064
  • Industry report
  • July 2013
  • by Euromonitor International

Volume sales of ear care products fell by 1% in 2012, a significantly poorer performance than that seen over the review period. Consumers’ cautious spending continued, and some consumers were less willing ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
Emergency Contraception in the United Kingdom

Emergency Contraception in the United Kingdom

  • $ 1 064
  • Industry report
  • July 2013
  • by Euromonitor International

In 2012, emergency contraception increased by 3% in current value terms, to reach £25 million. After the introduction of OTC emergency contraceptive pills in 2001, growth was initially rapid, as women ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA

Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA

  • $ 645
  • Industry report
  • July 2013
  • by Firstword Pharma

Scope of the Report European-based endocrinologists are currently getting to grips with two new products that have been rejected for approval in the US market. Novo Nordisk’s long-acting basal insulin ...

  • Industries : Drug and Medication, Pathology
  • Countries : Europe, United Kingdom, United States
PharmaPoint: Chronic Heart Failure - United Kingdom Drug Forecast and Market Analysis to 2022

PharmaPoint: Chronic Heart Failure - United Kingdom Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • June 2013
  • by Global Data

PharmaPoint: Chronic Heart Failure - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Chronic Heart Failure - United Kingdom ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • June 2013
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
2013 Drugs of Abuse Testing in the UK: Hospitals and Commercial Labs

2013 Drugs of Abuse Testing in the UK: Hospitals and Commercial Labs

  • $ 2 450
  • Industry report
  • June 2013
  • by Venture Planning Group

This new 260-page report from Venture Planning Group provides a comprehensive analysis of the UK drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
2013 Drugs of Abuse Testing in Europe: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers

2013 Drugs of Abuse Testing in Europe: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers

  • $ 6 500
  • Industry report
  • June 2013
  • by Venture Planning Group

This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, ...

  • Industries : Drug and Medication
  • Countries : Germany, United Kingdom, Italy, Spain
2013 Endocrine Function Testing Market in the UK: Hospitals and Commercial Labs

2013 Endocrine Function Testing Market in the UK: Hospitals and Commercial Labs

  • $ 2 450
  • Industry report
  • June 2013
  • by Venture Planning Group

This new 269-page report from Venture Planning Group provides a comprehensive analysis in the UK endocrine function market, including emerging tests, technologies, instrumentation, sales forecasts by country, ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
2013 Therapeutic Drug Monitoring (TDM) Market in the UK: Hospitals and Commercial Labs

2013 Therapeutic Drug Monitoring (TDM) Market in the UK: Hospitals and Commercial Labs

  • $ 2 450
  • Industry report
  • June 2013
  • by Venture Planning Group

This new 247-page report from Venture Planning Group provides a comprehensive analysis of the UK therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022

PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • May 2013
  • by Global Data

PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus - United Kingdom Drug ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • February 2013
  • by Global Data

PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022”. ...

  • Industries : General Medicine and Specialty Medicine, Pathology, Drug and Medication
  • Countries : United Kingdom
PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022

PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2013
  • by Global Data

PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis ...

  • Industries : Drug and Medication, Pathology
  • Countries : United Kingdom
Quad 2 (HIV) - Forecast and Market Analysis to 2022

Quad 2 (HIV) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2013
  • by Global Data

Quad 2 (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Quad 2 (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency ...

  • Industries : Pathology, Drug and Medication
  • Countries : France, Germany, Italy, Spain, United Kingdom, Japan, Brazil, China
Top Five Global Cardiovascular Drug Companies: Performance, Strategies and Competitive Analysis

Top Five Global Cardiovascular Drug Companies: Performance, Strategies and Competitive Analysis

  • $ 1 980
  • Industry report
  • December 2012
  • by Lucintel

The global cardiovascular drugs industry experienced average growth over the last five years and is expected to reach approximately US $174.8 billion in 2017, growing with a CAGR of 2.9% over the next ...

  • Industries : Drug and Medication
  • Countries : World, United Kingdom, United States, North America
OTC Medications – UK (2012)

OTC Medications – UK (2012)

  • $ 599
  • Industry report
  • December 2012
  • by Mintel

OTC Medications in UK by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2012. This market covers analgesics, cough/cold/flu, gastro-intestinal, ...

  • Industries : Retail
  • Countries : United Kingdom
KOL Insight: Hepatitis C: the race for the first interferon-free regimen

KOL Insight: Hepatitis C: the race for the first interferon-free regimen

  • $ 4 995
  • Industry report
  • November 2012
  • by Firstword Pharma

Analyzing the Hepatitis C Market Landscape After more than a decade of limited treatment options, the hepatitis C (HCV) market is on the cusp of a treatment revolution. In 2011, protease inhibitors-Incivek ...

  • Industries : Drug and Medication
  • Countries : United States, United Kingdom
Pharma and Payers – Building Better Relationships

Pharma and Payers – Building Better Relationships

  • $ 895
  • Industry report
  • September 2012
  • by Firstword Pharma

Changes in the healthcare landscape have put payers (public and private) under mounting pressure to reduce the cost of care, and given them much greater influence over market access to new medicines. ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
Future Horizons in the UK Nucleic Acid Testing Market: Supplier Shares and Sales Forecasts for 35 Tests and Applications by Market Segment

Future Horizons in the UK Nucleic Acid Testing Market: Supplier Shares and Sales Forecasts for 35 Tests and Applications by Market Segment

  • $ 5 900
  • Industry report
  • August 2012
  • by Venture Planning Group

Highlights Comprehensive 855-page market segmentation analysis of the UK NAT market.Major issues pertaining to the UK NAT laboratory practice, as well as key economic, regulatory, demographic, social and ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
Natural Products 2012

Natural Products 2012

  • $ 898
  • Industry report
  • June 2012
  • by Key Note Publications Ltd

Executive Summary This Key Note Market Report analyses the natural products industry in the UK. It calculates that the market is presently worth £750.4m. The market has failed to grow since 2007 and has ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
The 2012 UK Infectious Disease Testing Market

The 2012 UK Infectious Disease Testing Market

  • $ 5 900
  • Industry report
  • March 2012
  • by Venture Planning Group

This report presents a comprehensive analysis of the UK infectious disease testing market, including:Major issues pertaining to the UK laboratory practice, as well as key economic, regulatory, demographic, ...

  • Industries : Drug and Medication
  • Countries : United Kingdom

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.